Shares of Bionano Genomics BNGO rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 82.61% year over year to ($0.04), which beat the estimate of ($0.05).
Revenue of $3,990,000 up by 43.06% from the same period last year, which beat the estimate of $3,500,000.
Guidance
Bionano Genomics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Mar 23, 2021
Time: 04:30 PM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1438152&tp_key=1a103232b0
Price Action
Company's 52-week high was at $15.69
52-week low: $0.25
Price action over last quarter: Up 1580.17%
Company Overview
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
